According to IMARC Group’s latest report, titled “Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the global benign prostatic hyperplasia treatment market grew at a CAGR of 8% during 2014-2019. Looking forward, IMARC Group expects the global market to continue its moderate growth during 2020-2025.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Benign prostatic hyperplasia (BPH) refers to non-cancerous growth of the prostate gland that causes urethra blockage. This disorder generally results in the retention of urine, formation of bladder stones, incontinence due to overfilling, increased sensitivity of the bladder, and urinary tract infections. Some commonly used treatment methods for BPH include prescription drugs, mono drug and combination therapy, Phyto-therapies, and minimally-invasive (MI) and invasive surgeries. Resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants are some of the standard instruments used in BPH treatment surgeries.
Request Free Report Sample: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market/requestsample
The rising prevalence of urological disorders across the globe, coupled with the growing geriatric population, is currently driving the market growth. Furthermore, the increasing consumer awareness towards the availability of efficient and minimally-invasive treatment procedures for BPH is also propelling the market. Moreover, various advancements in the medical sector have led to the development of transurethral resection of the prostate (TURP) as an efficient treatment technique. TURP is an endoscopic electrosurgical procedure that removes a portion of the prostate gland to reduce the obstruction caused by abnormal growth. In addition to this, the rising healthcare expenditures and improving healthcare infrastructures will continue to drive the market growth in the coming years.
Competitive Landscape With Key Players:
The competitive landscape of the benign prostatic hyperplasia treatment market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- Abbott Laboratories
- Allergan Plc (AbbVie Inc.)
- Asahi Kasei Corporation
- Astellas Pharma Inc.
- Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
- Boston Scientific Corporation
- GlaxoSmithKline Plc
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
Key Market Segmentation:
Breakup by Treatment:
- Drug Class
- 5-Alpha-reductase Inhibitors (5-ARIs)
- Phosphodiesterase-5 Enzyme Inhibitors
- Minimally Invasive Surgeries
- Transurethral Resection of the Prostate (TURP)
- Transurethral Incision of the Prostate (TUIP)
- Transurethral Microwave Thermotherapy (TUMT)
- Robotic Surgeries
- Prostatic Urethral Lifts
- Laser Therapy
Breakup by Region:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800